FDA daily for Saturday, September 19, 2026
In this issue: 4 shortage updates and 29 label changes. 2 items touch categories MedGrid carries, and they come first.
For MedGrid's categories
Items in this issue that name a product category sold on MedGrid. Each links to its full FDA record; the chip opens that category's federal and state rules.
Drug shortages
FDA date:FDA updated 4 shortage entries on Fri, Sep 18: 2 new, 2 to be discontinued.
- Rivastigmine Film, Extended Release
Mylan Pharmaceuticals Inc., a Viatris Company
- Rivaroxaban For Suspension
Janssen Pharmaceuticals
- Rifampin Injection
Sanofi-Aventis U.S. LLC · Unavailable · Reason: Discontinuation of the manufacture of the drug
- Bupivacaine Hydrochloride Injection
ONESOURCE SPECIALTY PTE LTD · Available
Label updates
FDA date:29 drug labels took effect on Sat, Sep 5; 10 of the 25 read for this issue are for products in MedGrid's categories. Below: those, and labels carrying a boxed warning.
- Juyasuyon Invisible Sunscreen
HOMOSALATE,OCTOCRYLENE,OCTISALATE,BEMOTRIZINOL,AVOBENZONE · Guangdong Aimu Biological Technology Co., Ltd · TOPICAL
FDA did not answer for Approvals, Drug recalls, Device recalls, Clearances, Food and supplement recalls while this issue was written; those sections will fill in on a later visit.
How the FDA daily is written
Every issue is written from FDA's public data (openFDA) and nothing else: the counts, names, firms and reasons are FDA's own. openFDA posts each kind of record on its own delay, so each section covers one FDA date and says which. Shortages cover yesterday; approvals, drug and device recalls, and food and supplement recalls cover a week ago; device clearances and label changes cover two weeks ago. Every FDA date appears in exactly one issue. Complete response letters appear the day after FDA publishes a batch.
Subscribe with any feed reader, or point an email tool at the RSS feed to send each issue as a newsletter. Search any drug, device or company across every FDA dataset in the FDA data explorer.
